Global

  1. Global—English
  2. 中国—简体中文

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release
Press Release In the News Image Library Awards & Recognitions
  1. July 29, 2025

    Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — July 29, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the d...

    View more
  2. July 27, 2025

    Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – July 27, 2025   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical...

    View more
  3. July 23, 2025

    HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – July 23, 2025   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutica...

    View more
  4. June 23, 2025

    Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – June 22, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company commit...

    View more
  5. June 16, 2025

    China National Intellectual Property Administration Affirms Validity of Harbour BioMed’s Patent; Infringement Lawsuit Moves Forward

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — June 16, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the...

    View more
  6. April 10, 2025

    Harbour BioMed Appoints Youchen Chen as Chief Financial Officer

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — April 10, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to th...

    View more
  7. March 31, 2025

    Harbour BioMed Reports Full Year 2024 Financial Results

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 31, 2025   Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a glob...

    View more
  8. March 21, 2025

    Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies

    Shanghai, CN, Cambridge, MA, Rotterdam, NL – March 21, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company ...

    View more
  9. March 12, 2025

    Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies

    Cambridge, MA, Rotterdam, NL, Shanghai, CN – March 12, 2025   - Élancé Therapeutics aims to improve current obesi...

    View more
  10. March 11, 2025

    Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — March 10, 2025   Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to th...

    View more

Follow
Harbour BioMed
on WeChat

Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号 沪ICP备19015946号-1

FAMILY SITE

中文
ENG